MDGN, BBT, CNW, PPG - CRWESelect.com Stock News! Medgenics Inc., BB&T Corporation, Con-Way Inc., PPG Industries Inc. (Video Included Inside)

Medgenics, Inc. (AMEX: MDGN)

MDGN announced that the Company received notice of ‘Intention to Grant’ from the European Patent Office for the patent application entitled “USE OF DERMAL MICRO ORGANS,� with allowed claims covering a core element of its Biopump™ protein therapy technology.

“This patent is important as it protects key elements of our protein production technology. These claims provide significant protection for our proprietary technology and create significant barriers of entry to any would-be competitors,â€� stated Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics.

MDGN is developing and commercializing Biopumpâ„¢, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient’s own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia. Medgenics believes this approach has multiple benefits compared with current treatments, which include regular and costly injections of therapeutic proteins.

Medgenics has three long-acting protein therapy products in development based on this technology:

• EPODURE (now completing a Phase I/II dose-ranging trial) to produce and deliver erythropoietin for many months from a single administration, has demonstrated elevation and stabilization of hemoglobin levels in anemic patients for six to more than 36 months;
• INFRADURE (planning to commence a Phase I/II trial in Israel in 1H12 in hepatitis C) to produce a sustained therapeutic dose of interferon-alpha for use in the treatment of hepatitis;
• HEMODURE is a sustained Factor VIII therapy for the prophylactic treatment of hemophilia, now in development.

Medgenics intends to develop its innovative products and bring them to market via strategic partnerships with major pharmaceutical and/or medical device companies.

In addition to treatments for anemia, hepatitis and hemophilia, Medgenics plans to develop and/or out-license a pipeline of future Biopumpâ„¢ products targeting the large and rapidly growing global protein therapy market, which is forecast to reach $132 billion in 2013. Other potential applications for Biopumpsâ„¢ include multiple sclerosis, arthritis, pediatric growth hormone deficiency, obesity and diabetes.

For more information about MDGN please visit http://www.medgenics.com

****

BB&T Corporation (NYSE: BBT) reported fourth quarter net income available to common shareholders of $391 million, an increase of 88% compared to $208 million reported in the fourth quarter 2010. Earnings per diluted common share totaled $0.55, an increase of 83%, compared to $0.30 earned in the fourth quarter last year. For 2011, net income available to common shareholders was $1.3 billion, or $1.83 per diluted common share, compared with $816 million, or $1.16 per diluted common share, earned in 2010. This reflects an increase of 58% for both net income available for common shareholders and earnings per share.

BB&T Corporation operates as a financial holding company for Branch Banking and Trust Company that provides banking and trust services to individuals and businesses.

****

Con-Way, Inc. (NYSE: CNW) announced that it will release its financial results for the 2011 fourth quarter and full year, ended December 30, on Thursday, February 2, after the close of the stock market. The company will subsequently host a conference call for the investment community the following morning, Friday, February 3, at 8:30 a.m. Eastern Standard Time.

Con-way, Inc. together with its subsidiaries, provides transportation, logistics, and supply chain management services for a range of manufacturing, industrial, and retail customers.

****

PPG Industries, Inc. (NYSE: PPG) declared a regular quarterly dividend of 57 cents per share, payable March 12 to shareholders of record Feb. 17. This marks the company’s 454th consecutive dividend payment. PPG has paid uninterrupted annual dividends since 1899.

PPG Industries, Inc. vision is to continue to be the world’s leading coatings and specialty products company.

****************************

CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.

Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup/

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

MDGNcrweselect0122

Tags: AMEX: MDGN, Andrew L. Pearlman, anemia, arthritis, BB&T, Biopump, chronic diseases, Con-Way, diabetes, EPODURE, European Patent Office, HEMODURE, hemophilia, hepatitis C, INFRADURE, Intention to Grant, MDGN, Medgenics, medical device, NYSE: BBT, NYSE: CNW, NYSE: PPG, obesity, pediatric growth hormone deficiency, pharmaceutical, PPG Industries, protein therapy technology, sclerosis, Select, USE OF DERMAL MICRO ORGANS